Cancer Genetics, Inc.
If you purchased Cancer Genetics, Inc. securities and would like to join the action, please click "Join This Action" below.
CANCER GENETICS MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE MERGER OF CANCER GENETICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM
August 24, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cancer Genetics, Inc. (NASDAQ: CGIX) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with Cancer Genetics’s proposed merger with StemoniX, Inc.
Pursuant to the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock which will represent approximately 78% of the outstanding common stock of Cancer Genetics, subject to certain adjustments and prior to the effects of any financing. The current equity holders of Cancer Genetics will own 22% of the common stock of the combined company immediately following the consummation of the merger.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.